Dr. Campelo on the Rationale for the ALTA-1L Trial

Rosario Garcia Campelo, MD



Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, discusses a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer who were treated with brigatinib (Alunbrig) versus crizotinib (Xalkori).
 
The study, updated quality-of-life data of which were presented at the 2019 World Conferenc on Lung Cancer, demonstrated that brigatinib is favorable in these patients, including those with brain metastases. Overall, brigatinib was superior in improving health-related quality of life.

  <<< 2019 World Conference on Lung Cancer
Printer Printing...